Cholesterol Drug Can Reduce The Risk Of Heart Attack, Study Says; Study Hailed As "Landmark"; Prohibitive Cost An Issue?

By Carrie Winters - 20 Mar '17 19:01PM

Research shows that Repatha can reduce the risk of heart attack. It is also a medication that can lower LDL cholesterol also known as the bad cholesterol in the body.

According to a report, Repatha is a man-made antibody that can lessen the risk of heart attack, stroke and cardiovascular related deaths of 20 percent of the patients. This is a study that can lead more people in taking the drug according to a study that has been presented at the American College of Cardiology.

This new study about Repatha has been acclaimed by doctors. In fact, it has been indicated as a landmark study in aneditorial at The New England Journal of Medicine. Dr. Robin Dullaart, a researcher at the Universty of Groningen in the Netherlands was the one who wrote about it being a landmark study.

It is indicated that Repatha was approved in 2015 without the evidence that it actually can prevent heart attacks. It was approved because of the findings that it can reduce LDL cholesterol levels in the body. The decrease of this bad cholesterol had been promising and so was the reason for it to be approved.

In the recent study, patients that have heart diseases will take in Repatha with statin. It decreased the LDL cholesterol from 92 milligrams per deciliter. This level of cholesterol is low and doctors have not seen this type of reduction. Additionally, the reduction of LDL cholesterol when taking in Repatha is beneficial to the patients. However, as much as the drug can help in reducing the risk of heart attack, the drug has been said to be very expensive. The drug can cost $14,000 per year.

Meanwhile, it is reported that the trial for Repatha had actually made positive results in reducing the LDL cholesterol in the body. The patient with cardiovascular diseases needs to make proper decision to take the drug because of its price.

Fun Stuff

Join the Conversation

The Next Read

Real Time Analytics